Mission BioCapital Research
Investment Thesis
Mission BioCapital (MBC) provides early-stage capital to life science entrepreneurs and pairs it with a shared-lab platform where founders can run their first experiments. The firm's pitch is "Enabling Awesome": help scientists move from idea to key data faster and more efficiently, from the first bench experiment through to the clinic. The team describes itself as scientists, investors, founders and serial entrepreneurs who have launched and built dozens of early-stage life science companies together. Core principles are mentorship and collaboration, innovation and creativity in how deals are structured, and respect and support for founders.
Platform and Shared Labs
MBC is tied to a network of shared lab spaces: MBC BioLabs in the Bay Area, LabCentral in Cambridge, and BioLabs, a nationwide operator. Partners say the network serves over 385 startups in 8 geographies, and that companies started in it account for more than 20% of US Seed and Series A venture capital invested in life sciences. MBC BioLabs alone has hosted over 400 companies, with 173 drug programs taken to the clinic and over $20 billion raised. The labs are a primary sourcing channel: the firm says the best ways to reach it are through the shared labs, events, and introductions from portfolio companies.
Platinum Program
MBC runs an annual Platinum Program contest, with a $4 million pool in 2026. Winners receive up to $500,000 in seed funding, a lab bench and support services. Partners have included Eli Lilly, Ono Venture Investment and Alloy Therapeutics. The 2026 contest opening and the 2025 Platinum Ticket investments were announced in April 2026, and Canadian Platinum Tickets went to ImmunoBiochem and Orb Therapeutics at BIOTECanada.
Stage Focus
Seed and early-stage, with a heavy tilt toward company creation. Partners often take interim operating roles, board seats or founding CEO roles. Follow-on participation is common in later rounds, for example co-leading Breye Therapeutics' Series A alongside Novo Holdings.
Check Size
Not published. The Platinum Program offers up to $500,000 in seed funding, and Fund V is $275 million, which implies initial checks from the high hundreds of thousands to low single-digit millions with reserves for follow-ons. This is an inference, not a stated range.
Lead Tendency
Both. MBC leads and co-leads early rounds and takes board seats, and partners sit on boards at most core portfolio companies. It also syndicates, co-leading Breye's Series A with Novo Holdings.
Recent Activity
- Announced Fund V ($275M) in November 2021; the firm describes itself as investing out of its fifth fund.
- Opened an office and incubator partnership at BioInnovation Institute in Copenhagen in April 2025, expanding into the Nordics and Europe.
- Portfolio exits: Dren Bio asset acquired by Sanofi (March 2025) and SiteOne Therapeutics acquired by Lilly (May 2025). Tidal Therapeutics was acquired by Sanofi in 2021.
- Co-led Breye Therapeutics ApS's oversubscribed Series A alongside Novo Holdings (2026).
- Launched the 2026 Platinum Program contest in April 2026.
Portfolio Highlights
The portfolio is mostly therapeutics, plus tools and a few ag and food companies. Notable names include Alector (public), Caribou Biosciences (public), Principia Biopharma (acquired), Zymergen (public), Atreca (public), Mammoth Biosciences, Dren Bio, SiteOne Therapeutics, Tidal Therapeutics, QurAlis, Tune Therapeutics, Circle Pharma and Bolt Threads. The portfolio page lists 70 distinct companies.
Team
- Zach Collins, PhD: Partner, San Francisco; early-stage biopharma, board roles at SiteOne, Cavalry, Nuvig, Jupiter and Telo
- Douglas Crawford, PhD: Managing General Partner, San Francisco; runs MBC BioLabs, founded predecessor Mission Bay Capital
- Robert Blazej, PhD: Partner, San Francisco; leads firmwide diligence, co-founded Allopartis
- Peter Parker: Managing General Partner, Cambridge; life science tools, therapeutics and drug delivery; co-founded LabCentral
- Steve Tregay, PhD: Managing General Partner, Cambridge; founding CEO of Arclight, founder of FORMA Therapeutics
- Johannes Fruehauf, MD PhD: General Partner, Cambridge; co-founder of LabCentral, CEO of BioLabs
- Ulrik B. Nielsen, PhD: General Partner, Cambridge; co-founded Tidal and Merrimack
- Cassidy Blundell, PhD: Partner, Cambridge; therapeutics
- Jennifer Griffin, PhD: Partner, Cambridge; fund strategy and investor relations
- Michael Taylor, PhD: Operating Partner, Cambridge; former CEO of Deciphera
- Chaya Patel, PhD: Principal, Cambridge
- Clay Rowland: Investment Associate, San Francisco
- Josephine Brysting, PhD: Investment Analyst, Copenhagen
Decision Process
Partnership model with several managing general partners and general partners. Deals are led by a sponsoring partner who typically joins the board, with firmwide diligence coordinated by a partner. Warm introductions through portfolio companies and the shared labs are the stated preferred route.
Founder Preferences
Scientist-founders at the earliest stage, including those with "nothing more than a dream and a credit card." The firm emphasizes backing exceptional entrepreneurs from all walks of life and has supported programs for underrepresented and female founders (MLSC sponsorship, LabCentral Ignite).
Geographic Focus
Offices in San Francisco and Cambridge, MA, plus Copenhagen since 2025. Focus is US biotech hubs (Bay Area, Boston/Cambridge) with growing European and Nordic sourcing, and Canadian reach through the Platinum Program.